Andrew R. Allen, See Remarks at Clovis Oncology, Inc. (CLVS), sold 80,000 shares at $65.27 ($5.3M) on 2015-01-16, disclosed to the SEC on 2015-01-21.
Scheduled sale ($5.3M) by See Remarks under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Negative factors outweigh the positive ones.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $65.00 | 300 | $20K | 0.4% |
| 2 | $65.27 | 30,524 | $2.0M | 37.8% |
| 3 | $66.26 | 49,176 | $3.3M | 61.8% |
| Total | $65.88 avg | 80,000 | $5.3M | 100% |
| Filing → |
| CLVS | SELL | 2015-01-20 | $3.2M | — | Filing → |
| CLVS | SELL | 2013-06-07 | $1.5M | — | Filing → |
| CLVS | BUY | 2011-11-21 | $50K | — | Filing → |